ThromboGenics' Partner Alcon Launches JETREA® for the Treatment of Symptomatic Vitreomacular Adhesion in Canada

ThromboGenics' Partner Alcon LaunchesThromboGenics' Partner Alcon Launches JETREA® for the Treatment of Symptomatic Vitreomacular Adhesion in Canada PR Newswire LEUVEN, Belgium, November 20, 2013 ®Canada is the first market launch for JETREA outside the US and Europe ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that its partner Alcon has launched JETREA® (ocriplasmin) for the treatment of symptomatic vitreomacular adhesion (VMA) in Canada. Canada is the first market where JETREA® has been launched outside the US and Europe. Symptomatic VMA is estimated to affect up to 15,000 people in Canada [1] ®each year . Health Canada approved JETREA on August 13, 2013 following priority review. Alcon, a division of Novartis, acquired the rights to commercialize ®JETREA outside the United States in March 2012. It launched the drug in the UK, its first European market, in April, followed by launches in Germany, Denmark, Finland, Norway and Sweden. ThromboGenics is commercializing the drug in the US and launched ®JETREA in the US in mid-January 2013 where it is approved for the treatment of patients with symptomatic vitreomacular adhesion (VMA).